Cygnal's Pearl Huang recruits former Merck colleague John Wagner to realize broad exoneural vision in the clinic
Long before her current life as CEO of Flagship startup Cygnal, Pearl Huang had the title of integrator at Merck’s oncology franchise.
Tasked with overseeing the transition of experimental drugs from preclinical to early clinical, she worked closely with John Wagner — an expert in clinical pharmacology — to faciliate early development and biomarker research around cancer programs.
Now, as Cygnal itself is on the verge of the clinic, she’s reuniting with Wagner to steer into the clinic a different class of cancer drugs: ones targeting the role of the peripheral nervous system in cancer pathogensis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.